Sanofi (France) and Regeneron Pharmaceuticals, Inc. Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and...

---

Quest Diagnostics Launches Novel Rheumatoid Arthritis Tests

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, recently announced the availability of two new blood tests for aiding the early diagnosis of...Read the…

---

Europeans throw cold water on Pfizer’s hot streak with Xeljanz rejection

European authorities have battered expectations for Pfizer's rheumatoid arthritis pill Xeljanz, spurning the drug giant's request for approval over concerns about the risk-benefit profile. The surpris…

---

Pfizer arthritis drug rejected by European regulators

(Reuters) - European regulators declined to approve marketing of Pfizer Inc's new rheumatoid arthritis treatment Xeljanz, citing the risks of the drug compared with its potential benefit, the company…

---